網宿科技(300017.SZ)完成註銷8.79萬份股票期權
格隆匯11月27日丨網宿科技(300017.SZ)公佈,公司第四屆董事會第三十七次會議審議通過了《關於調整公司<2017年股票期權與限制性股票激勵計劃>首次授予激勵對象、股票期權數量暨回購註銷部分限制性股票的議案》,鑑於公司2017年股票期權與限制性股票激勵計劃(首次授予期權簡稱:網宿JLC6,首次授予期權代碼:036275)首次授予股票期權的10名激勵對象因個人原因離職,經與會董事審議,同意取消上述10名人員的激勵對象資格,並註銷已授予其的股票期權約8.79萬份。
2019年11月27日,經中國證券登記結算有限責任公司深圳分公司審核確認,上述股票期權註銷手續已辦理完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.